Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126

Jens Vogel-Claussen, Barjor Gimi, Dmitri Artemov, Zaver M Bhujwalla

Research output: Contribution to journalArticle

Abstract

The effects of the anti-vascular agent ZD6126 were studied in volume matched subcutaneous DU-145 human prostate cancer xenografts in SCID mice using two different MRI techniques, diffusion and vascular imaging. Diffusion weighted MRI was performed before and at 24 h, 48 h and 72 h following a single dose of 200 mg/kg. Tumor vascular volume and permeability surface area product (PSP) were determined 24 h post antivascular therapy following an identical dose using dynamic contrast enhanced MRI of the macromolecular contrast agent albumin-gadolinium diethylenetriaminepentaacetate (albumin-GdDTPA). Consistent with the mechanism of action of ZD6126, significantly lower vascular volume was detected at 24 h whereas diffusion changes were evident at 48 h. Diffusion MRI findings correlated well with histological determination of the necrotic fraction in the tumors by 48 h. Both diffusion and vascular imaging are useful noninvasive techniques to detect response of tumors to antivascular therapy with ZD6126 in the DU-145 human prostate cancer xenograft model.

Original languageEnglish (US)
Pages (from-to)1469-1475
Number of pages7
JournalCancer Biology and Therapy
Volume6
Issue number9
StatePublished - Sep 2007

Fingerprint

Diffusion Magnetic Resonance Imaging
Blood Vessels
Heterografts
Neoplasms
Prostatic Neoplasms
SCID Mice
Gadolinium
Capillary Permeability
Therapeutics
Tumor Burden
Contrast Media
Albumins
N-acetylcochinol-O-phosphate

Keywords

  • Antivascular treatment
  • Diffusion-weighted MRI
  • Permeability
  • Prostate cancer xenograft
  • Vascular volume
  • ZD6126

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126. / Vogel-Claussen, Jens; Gimi, Barjor; Artemov, Dmitri; Bhujwalla, Zaver M.

In: Cancer Biology and Therapy, Vol. 6, No. 9, 09.2007, p. 1469-1475.

Research output: Contribution to journalArticle

@article{b32ac876f4ae4adbab0738c05be8849e,
title = "Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126",
abstract = "The effects of the anti-vascular agent ZD6126 were studied in volume matched subcutaneous DU-145 human prostate cancer xenografts in SCID mice using two different MRI techniques, diffusion and vascular imaging. Diffusion weighted MRI was performed before and at 24 h, 48 h and 72 h following a single dose of 200 mg/kg. Tumor vascular volume and permeability surface area product (PSP) were determined 24 h post antivascular therapy following an identical dose using dynamic contrast enhanced MRI of the macromolecular contrast agent albumin-gadolinium diethylenetriaminepentaacetate (albumin-GdDTPA). Consistent with the mechanism of action of ZD6126, significantly lower vascular volume was detected at 24 h whereas diffusion changes were evident at 48 h. Diffusion MRI findings correlated well with histological determination of the necrotic fraction in the tumors by 48 h. Both diffusion and vascular imaging are useful noninvasive techniques to detect response of tumors to antivascular therapy with ZD6126 in the DU-145 human prostate cancer xenograft model.",
keywords = "Antivascular treatment, Diffusion-weighted MRI, Permeability, Prostate cancer xenograft, Vascular volume, ZD6126",
author = "Jens Vogel-Claussen and Barjor Gimi and Dmitri Artemov and Bhujwalla, {Zaver M}",
year = "2007",
month = "9",
language = "English (US)",
volume = "6",
pages = "1469--1475",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126

AU - Vogel-Claussen, Jens

AU - Gimi, Barjor

AU - Artemov, Dmitri

AU - Bhujwalla, Zaver M

PY - 2007/9

Y1 - 2007/9

N2 - The effects of the anti-vascular agent ZD6126 were studied in volume matched subcutaneous DU-145 human prostate cancer xenografts in SCID mice using two different MRI techniques, diffusion and vascular imaging. Diffusion weighted MRI was performed before and at 24 h, 48 h and 72 h following a single dose of 200 mg/kg. Tumor vascular volume and permeability surface area product (PSP) were determined 24 h post antivascular therapy following an identical dose using dynamic contrast enhanced MRI of the macromolecular contrast agent albumin-gadolinium diethylenetriaminepentaacetate (albumin-GdDTPA). Consistent with the mechanism of action of ZD6126, significantly lower vascular volume was detected at 24 h whereas diffusion changes were evident at 48 h. Diffusion MRI findings correlated well with histological determination of the necrotic fraction in the tumors by 48 h. Both diffusion and vascular imaging are useful noninvasive techniques to detect response of tumors to antivascular therapy with ZD6126 in the DU-145 human prostate cancer xenograft model.

AB - The effects of the anti-vascular agent ZD6126 were studied in volume matched subcutaneous DU-145 human prostate cancer xenografts in SCID mice using two different MRI techniques, diffusion and vascular imaging. Diffusion weighted MRI was performed before and at 24 h, 48 h and 72 h following a single dose of 200 mg/kg. Tumor vascular volume and permeability surface area product (PSP) were determined 24 h post antivascular therapy following an identical dose using dynamic contrast enhanced MRI of the macromolecular contrast agent albumin-gadolinium diethylenetriaminepentaacetate (albumin-GdDTPA). Consistent with the mechanism of action of ZD6126, significantly lower vascular volume was detected at 24 h whereas diffusion changes were evident at 48 h. Diffusion MRI findings correlated well with histological determination of the necrotic fraction in the tumors by 48 h. Both diffusion and vascular imaging are useful noninvasive techniques to detect response of tumors to antivascular therapy with ZD6126 in the DU-145 human prostate cancer xenograft model.

KW - Antivascular treatment

KW - Diffusion-weighted MRI

KW - Permeability

KW - Prostate cancer xenograft

KW - Vascular volume

KW - ZD6126

UR - http://www.scopus.com/inward/record.url?scp=42549110427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549110427&partnerID=8YFLogxK

M3 - Article

C2 - 17881899

AN - SCOPUS:42549110427

VL - 6

SP - 1469

EP - 1475

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 9

ER -